Medical therapy of inflammatory bowel disease

Digestion

Volumn 59, Issue 5, 1998, Pages 453-469

  Rutgeerts, Paul ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Drug therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOKINE; CYTOKINE ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

CROHN DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HEALING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RECURRENCE; REMISSION INDUCTION; SAFETY; TREATMENT OUTCOME;

EID: 0031926192     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007523     Document Type: Review

References (167)

1. Coremans G, Rutgeerts P, Geboes K, Van Den Oord J, Ponette E, Vantrappen G: The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease. Gastrointest Endosc 1984;30:167-172.
2. Truelove SC, Witts LJ: Cortisone in ulcerative colitis: Final report on a therapeutic trial. BMJ 1955;2:1041-1048.
3. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989;298:(6666): 82-86.
4. Danielsson Å, Löfberg R, Persson T, Salde L, Schioler R, Suhr O, Willen R: A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27:9-12.
5. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME: Microscopic activity in ulcerative colitis: What does it mean? Gut 1991;32:174-178.
6. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
7. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW: Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-296.
8. Mary JY, Modigliani R: Development and Validation of an endoscopie index of the severity for Crohn's disease: A prospective multicentre study. Gut 1989;30:983-989.
9. Modigliani R: Endoscopie management of inflammatory bowel disease. Am J Gastroenterol 1994;89:S53-S65.
10. Brattsand R: Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407-414.
11. Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996;334:841-848.
12. Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997;40:775-781.
13. Campieri M, Corbelli C, Giochetti P, Brignola C, Belluzzi A, Di Febo G, Zagni P, Brunetti G, Miglioli M, Barbara L: Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992;37:1890-1897.
14. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Bar-bara L: Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32:929-931.
15. Williams CN, Haber G, Acquino JA: Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and mea-surement of extent of spread using 99Tc-labelled 5-ASA suppositories. Dig Dis Sci 1987;32:71-75S.
16. Löfberg R, Östergaard-Thomsen O,Langholtz E, Schiöler R, Danielsson Å, Suhr O, Olsson O, Graffner H, Påhlman L, Raab Y, Matzen P, Andersen T, Möller-Pedersen JF, Halvorsen L, Hovdenak N, Malchow-Möller A, Willen R, Persson T, Seidegård C, Nordström H: Budesonide versus prednisolone enema in active distal ulcerative colitis: A comparative eight week study. Gut 1993;34(suppl 1):S41-S46.
17. Pruitt R, Katz S, Bayless T, Levine J: Repeated use of budesonide enema is safe and effective for the treatment of acute tlares of distal ulcerative colitis. Gastroenterology 1996;110:A995.
18. Jarnerot G, Lennard-Jones J, Bianchi-Porro G, Brynskov J, Campieri M, Present D: Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 1991;4:93-98.
19. Biddle WL, Miner PB Jr: Long term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990;99: 113-118.
20. Mulder CJJ, Fockens P, van der Heide H, Tytgat GNJ: A controlled randomized trial of beclomethasondipropionate (3 mg) versus 5-aminosalicylic acid (1 g) versus the combination of both (3 MG/1 G) as retention enemas in active distal ulcerative colitis. Gastroenterology 1994; 106:A739.
21. Sandborn WJ, Tremaine WJ, Schroeder KW, Baits KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR: A placebo-controlled trial of cyclosporin enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-1435.
22. Winter TA, Dalton HR, Merrett MN, Campbell A, Jewell DP: Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. Scand J Gastroenterol 1993;28: 701-704.
23. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J: Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first line therapy: A pilot study. Aliment Pharmacol Ther 1997; 11:663-671.
24. Bjorck S, Dahlstrom A, Johansson L, Ahlman H: Treatment of the mucosa with local anaesthetics in ulcerative colitis. Agents-Actions 1992;spec No:C60-72.
25. Peeters M, Geboes K, Baert F, D'Haens G, Ectors N, Rutgeerts P: High dose ropivacaine treatment in active ulcerative colitis induces a global reduction of histological inflammation. Gastroenterology 1997;112:A1060.
26. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, Harig JM, Keshavarzian A, Robinson M, Sellin JH, Weinberg D, Vidican DE, Flemal KL, Rademaker A: Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomized, placebo-controlled trial. Gut 1997;40:485-491.
27. Scheppach W and German-Austrian SCFA study group: Treatment of distal ulcerativc colitis with short-chain fatty acid enemas. A placebo-controlled trial. Dig Dis Sci 1996;41: 2254-2259.
28. Sutherland LR, May GR, Shaffer EA: Sulphasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerativc colitis. Ann Intern Med 1993;118:540-549.
29. Green JRB, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJF, Parkins KJ, Tylor MD and the Abacus investigator group: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998;114:15-22.
30. Wadworth AN, Fitton A: Olsalazine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 1991:41:647-664.
31. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Avery Jones JE: Outpatient treatment of ulcerative colitis: Comparison between three doses of oral prednisolone. Br Med J 1962;ii:441-446.
32. Löfberg R, Danielsson Å, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110: 1713-1718.
33. Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, Jewell DP: Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.
34. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
35. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
36. Kornbluth A, Lichtiger S, Present D, Hanauer S: Long-term results of oral cyclosporin in patients with severe ulcerative colitis: A double-blind randomized multicenter trial. Gastroenterology 1994;106:A714.
37. Baert F, Hanauer S: CyA in severe steroid-resistant UC: Long-term results of therapy. Gastroenterology 1994;106:A648.
38. Vermeire S, Rutgeerts P: Cylcosporine monotherapy is effective in the treatment of severe ulcerative colitis. Inflam Bowel Dis 1996;2: 253-254.
39. D'Haens G, Lemmens L, Hiele M, Vandeputte L, Nevens F, Peeters M, Vermeire S, Baert F, Geboes K, Rutgeerts P: Intravenous cyclosporine (CyA) monotherapy versus intravenous methylprednisolone (MP) monotherapy in severe ulcerative colitis: A randomized double blind controlled trial (abstract). Gastroenterology 1998;114:A963.
40. Svanoni F, Bonassi U, Bagnola F, Caporuscio S: Effectivcness of eyclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC) (abstract). Gastroenterology 1998;114: A1096.
41. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811-815.
42. Harries AD, Baird A, Rhodes J: Non-smoking: A feature of ulcerative colitis. BMJ 1982;284: 706.
43. Logan RFA, Edmond M, Somerville KW, Langman MJ: Smoking and ulcerative colitis. BMJ 1984;288:71-73.
44. Motley RJ, Rhodes J, Ford GA, Wilkinson SP, Chesner IM, Asquith P, Hellier MD, Mayberry JF: Time relationships between cessation of smoking and onset of ulcerative colitis. Digestion 1987;37:125-127.
45. Motley RJ, Rhodes J, Kay S, Morris TJ: Late presentation of ulcerative colitis in ex-smokers. Int J Colorectal Dis 1988;3:171-175.
46. Roberts CJ, Diggle R: Non-smoking: A feature of ulcerative colitis. BMJ 1982;285:440.
47. de Castella H: Non-smoking: A feature of ulcerative colitis. BMJ 1982;284:1706.
48. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DP, Hurt RD: Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:364-371.
49. Casellas F, Papo M, Guarner F, Antolin M, Segura RM, Armengol JR, Malagelada JR: Effects of thromboxane inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:221-226.
50. Hawthorne AB, Logan RFA, Hawkey CJ, Foster PN, Axon ATR, Swarbrick ET, Scott BB, Lennard-Jones JE: Randomised trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-22.
51. Oren R, Arger N, Ocles S, Moshkowitz M, Keter D, Pomeranz S: Methotrexate in chronic active ulcerative colitis: A double-blind randomised Israeli multicentre trial. Gastroenterology 1996;110:1416-1421.
52. Trallori G, Messori A, Scuffi C, Bardazzi G, Silvano R, d'Albasio G, Pacini F: 5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: A meta- and economic analysis. J Clin Gastroenterol 1995;20:257-259.
53. D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, Bascaino A, Mazzacca G: 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: A double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990;85:1079-1082.
54. Rutgeerts P and International Study Group: Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989;3:183-191.
55. Travis SPL, Tysk C, Sylva HJD, Sandberg-Gertzén H, Jewell DP, Järnerot G: Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-1286.
56. Dissanayakc AS, Truelovc SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine(Salazopyrin). Gut 1973;14:923-926.
57. Ardizzone S, Imbese V, Molteni P, Bollani S, Porro GB: Is therapy always necessary for patients with ulcerative colitis in remission? Gastroenterology 1996;110:A856.
58. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Illstrup D: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-239.
59. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F: Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after proctocolectomy. Arch Surg 1996;131:497-500.
60. Madden MV, McIntyre AS, Nicholls RJ: Double-blind trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-1196.
61. Merrett MN, Mortensen N, Kettlewell M, Jewell DO: Smoking may prevent pouchitis in patients with restorative protocolectomy for ulcerative colitis. Gut 1996;38:362-364.
62. Stahlberg D, Gullberg K, Liljeqvist L, Hellers R: Pouchitis following pouch operation for ulcerative colitis: Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012-1018.
63. Sandborn WJ: Pouchitis following ileal pouchanal anastomosis: Definition, pathogenesis and treatment. Gastroenterology 1994;107:1856-1860.
64. Sagar PM, Dozois RR, Wolff BG: Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Dis Colon Rectum 1996;39:893-898.
65. Sachar DB, Andrews H, Farmer RG, Pallone F, Pena AS, Prantera C, Rutgeerts P: Proposed classification of patient subgroups in Crohn's disease. Working Team Report 4. Gastroenterol Int 1992;3:141-154.
66. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National Co-operative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-869.
67. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H: European Co-operative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-266.
68. Van Hees PAM, Van Lier HJJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, Bakker JH, Van Tongeren JH: Effect of sulfasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 1981;22:404-409.
69. Rijk MC, Van Hogezand RA, Van Lier HJJ, Van Tongeren JH: Sulphasalazine and prednisone compared with Sulphasalazine for treating active Crohn's disease. Ann Intern Med 1991; 114:445-450.
70. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL: Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993;104:1293-1301.
71. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR: A randomized, double-blind placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-282.
72. Martin F, Sutherland LR, Beck IT, Anderson AH, Williams CN, Saibil F, Battenman J, Lemire S: Oral 5-ASA versus prednisolone in short-term treatment of Crohn's disease: A multicentre controlled trial. Can J Gastroenterol 1990;4:452-457.
73. Gross V, Roth M, Fischback W, Purrmann J, Weber A, Gierend M, Hartmann F, Schölmerich J: Comparison between high dose 5-aminosalicylic acid (5-ASA) and 6-methylprednisolone in active Crohn's disease. Gastroenterology 1994;106:A694.
74. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E: Clinical, biological and endoscopie picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-818.
75. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C: Endoscopie monitoring of Crohn's disease: A prospective, randomized clinical trial. Gastroenterology 1992;102:1647-1653.
76. Edsbäcker S, Wollmer P, Nilsson Å, Nillson M: Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993;104:A695.
77. Naber AHJ, Olaison G, Smedh K, Jansen JBMJ, Sjödahl R: Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease. Gastroenterology 1996;110: A977.
78. Moellmann HW, Hochhaus G, Tromm A, Moellmann A, Derendorf H, Barth J, Froehlich P, Ecker KW, Lindemann A: Pharmacokinetics and evaluation of systemic side effects of budesonide after oral administration of modified release capsules in healthy volunteers, ileostoma patients and patients with Crohn's disease. Gastroenterology 1996;110:A972.
79. Löfberg R, Danielsson Å, Salde L: Oral budesonide in active ileal Crohn's disease: A pilot trial with a topically acting steroid. Aliment Pharmacol Ther 1993;7:611-616.
80. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T and the Canadian Inflammatory Bowel Disease Study Group: Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-841.
81. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson Å, Goebell H, Østergaard-Thomsen O, Lorenz-Meyer H, Hodgson H, Persson T, Seidegård C: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842-845.
82. Campieri C, Ferguson A, Doe W and the Global Budesonide Study Group: Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997;41:209-214.
83. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Nylander I: Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week international randomised double-blind multicentre trial. Gastroenterology 1997;112: A1104.
84. Gross V, Andus T, Caesar I, Manns M, Lochs H, Genser D, Schulz J, Bår U, Uberschaer B, Weber A, Gierend M, Ewe K, Schölmerich J: Oral PH-modified release budesonide vs 6-methyl prednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:905-909.
85. Gross V, Caesar I, Andus T, Vogelsang H, Adler G, Malchow H, Weber A, Gierend M, Schölmerich J and the German/Austrian Budesonide Study Group: Dose-finding study with oral budesonide in patients with active Crohn's ileocolitis. Gastroenterology 1997; 112:A986.
86. Korelitz BI, Present DH: A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: Origins at the Mount Sinai Hospital. Mt Sinai Med J 1996;6:191-201.
87. Harper PH, Truelove SC, Lee ECG, Kettlewell MGW, Jewell DP: Split ileostomy and ileocolostomy for Crohn's disease of the colon and ulcerative colitis: A 20-year survey. Gut 1983; 24:106-113.
88. Rutgeerts P, Geboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-774.
89. Sartor RB: Insights into the pathogenesis of inflammatory bowel diseases provided by new rodent models of spontaneous colitis. Inflam Bowel Dis 1995;1:64-75.
90. Elliott PR, Burnham WR, Berghouse LM, Lennard-Jones JE, Langman MJ: Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982;23:132-134.
91. Shatter JL, Hughes S, Linaker BD, Baker RD, Turnberg LA: Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25:203-205.
92. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, Wilkinson S, Rhodes P, Roberts G, Lawrie BW: Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994;35:363-368.
93. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP: Controlled trial of antimycobacterial therapy in Crohn's disease: Clofazimine versus placebo. Dig Dis Sci 1991;36:449-453.
94. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regi-men. Am J Gastroenterol 1994;89:513-518.
95. Basilisco G, Ranzi T, Campanini MC, Piodi L, Bianchi PA: Controlled trial of rifabutin in Crohn's disease. Curr Ther Res 1989;46:245-250.
96. Rutgeerts P, Geboes K, Vantrappen G, Van Isveldt J, Peeters M, Penninckx F, Hiele M: Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol 1992;15:24-28.
97. Graham DY, Al-Assi MT, Robinson M: Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis. Gastroenterology 1995;108:A826.
98. Moss AA, Carbone JV, Kressel HY: Radiologic and clinical assessment of broadspectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978;131(5):787-790.
99. Ursing B, Kamme C: Metronidazole for Crohn's disease. Lancet 1975;i:775-777.
100. Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79: 357-365.
101. Brandt LJ, Bernstein LH, Boley SS, Frank MS: Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982;83:383-387.
102. Jakobovitis J, Shuster M: Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-540.
103. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E: Metronidazole in Crohn's disease: A double-blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-127.
104. Ursing B, Alm T, Barany F, Bergelin I, Ganrot Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982;83:550-562.
105. Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Barnes P, Lennard-Jones JE: Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: A prospective randomized study. Dis Colon Rectum 1985;28:81-85.
106. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32: 1071-1075.
107. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-332.
108. Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY and the GETAID: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology 1997;112:A951.
109. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta analysis of enterai nutrition as primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-1067.
110. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
111. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine: A long-term randomized double blind study. N Engl J Med 1980;302:981-987.
112. Pearson DC, May GR, Pick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis. Ann Intern Med 1995;122:132-142.
113. O'Donoghue DP, Dawson AM, Powel-Tuck J, Bown RL, Lennard-Jones JE: Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;ii:955-957.
114. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678.
115. Bouhnik Y, Lémann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347:215-219.
116. Ewe K, Press AG, Singe CC, Stufler M, Vebersehaer B, Hommel G, Meyer-zum-Buschenfelde KH: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-372.
117. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34: 1081-1085.
118. Colonna T, Korelitz BI: The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-366.
119. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P: Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112:1475-1481.
120. Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ: Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63-68.
121. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mayes DC, Lipsky JJ: An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109(6):1808-1817.
122. Connell WR, Kinlen LJ, Ritchie JK, Balkwill A, Lennard-Joncs JE, Kamm MA: Cancer risk from azathioprine in inflammatory bowel disease. Gastroenterology 1994;106:A667.
123. Francella A, Dayan A, Rubin P, Chapman M, Present D: 6-Mercaptopunne (6-MP) is safe therapy for child bearing patients with IBD: A case controlled study. Gastroenterology 1996; 110:A909.
124. Kozarek RA, Patterson DJ, Gelfand MD: Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-356.
125. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD for the North American Crohn's Study Group Investigators: Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332: 292-297.
126. Brynskov J, Freund L, Rasmussen SN: Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991;26:689-695.
127. Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gilles R, Valberg B, Irvina EJ: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330:1846-1851.
128. Jewell DP, Lennard-Jones JE, and the cyclosporin study group of Great Britain and Ireland: Oral cyclosporin for chronic active Crohn's disease: A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994;6: 499-505.
129. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR and the European Study Group: European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. Gastroenterology 1995;109: 774-782.
130. Lichtiger S: To use or not to use cyclosporine-A. That is the question. Inflam Bowel Dis 1995;1:331-334.
131. Hanauer SB, Smith MB: Rapid closure of Crohn's disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993;88: 646-649,
132. Markowitz J: Cyclosporine lacks therapeutic efficacy in highly destructive perianal Crohn's disease associated with Crohn's disease (CD). Am J Gastroenterol 1993;88: 1620-1624.
133. Elson CO: The basis of current and future therapy for inflammatory bowel disease. Am J Med 1996;100:656-662.
134. Sands BE: Biologic therapy for inflammatory bowel disease. Inflam Bowel Dis 1997;3:95-113.
135. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:1:9-135.
136. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, De Woody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337: 1029-1035.
137. D'Haens GR, van Deventer SJH, Van Hogezand R, Chalmers DM, Braakman TAJ, Schaible TF, Rutgeerts PJ: Anti-TNFa monoclonal antibody (cA2) produces endoscopie healing in patients with treatment-resistant, active Crohn's disease. Gastroenterology 1998;114:A964.
138. Baert F, D'Haens G, Geboes K, Ectors N, Rutgeerts P: TNF-α antibody therapy causes a fast and dramatic decrease of histologic colonie inflammation in Crohn's disease but not in ulcerative colitis. Gastroenterology 1996;110:A859.
139. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA, Hawkey CJ: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-524.
140. van Deventer SJ, Elson CO, Fedorak RN and The Crohn's Disease Study Group: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-389.
141. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams NC, Jacyna M, Lashner BA, Cohard M, Kilian A, Lebaut A, Hanauer SB: A safety and efficacy study of recombinant human interleukin-10 (rhuIL-10) treatment in 329 patients with chronic active Crohn's disease. Gastroenterology 1998;114:A1080.
142. Bank S, Sninsky C, Robinson M, Katz S, Singleton J, Miner P, Safdi M, Galandink S, Hanauer S, Varilek G, Sands B, Buchman A, Rogers V, Salzberg B, Caï B, Rogge H, Schwertschlag U: Safety and activity evaluation of rh IL-11 in subjects with active Crohn's disease. Gastroenterology 1997;112: A927.
143. Yacyshyn B, Woloschuk B, Yacyshyn MB, Martini D, Doan K, Tami J, Bennett F, Kisner D, Shanahan W: Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease. Gastroenterology 1997;112:A1123.
144. Stronkhorst A, Radema S, Yong SL, Byl H, ten Berge IJM, Tytgat GNJ, van Deventer SJH: CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study. Gut 1997;40:320-327.
145. Messier A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, D'Albasio G, de Simone G, Martini N: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:692-698.
146. Steinhart AH, Hemphill D, Greenberg GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:2116-2124.
147. Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soulé JC, Galmiche JP, Lerebours E, Descos L, Viteau JM: Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. Gastroenterology 1993;104: 435-439.
148. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA and the Pentasa Crohn's disease Compassionate Use Study Group: Long term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol 1993;88:1343-1350.
149. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaiche J, Mary JY, for GETAID: Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688-693.
150. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T, and the Canadian IBD-group: Oral budesonide as mainenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996:110:45-51.
151. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson Å, Olaison G, Jewell D, Østergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seidegard C: Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease: A placebo-controlled one-year study. Gut 1996;39:82-86.
152. Rutgeerts P, D'Haens G, van Deventer SJH, Present DH, Mayer L, Hanauer SB, Braakman TAJ, De Woody KL, Schaible TF, Targan SR: Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997;112:A1078.
153. Belluzzi A, Brignola C, Campieri M, Fera A, Boschi S, Miglioli M: Effect of an enteric-coated fish-oil preparation in relapses in Crohn's disease. N Engl J Med 1996;334: 1557-1560.
154. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V, Carr L, and study group members of the German Crohn's Disease Study Group: Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. Scand J Gastroenterol 1996;31:778-785.
155. Rutgeerts P, Geboes K, Vantrappen G: Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:666-672
156. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:456-463.
157. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenteroiogy 1998;114:262-267.
158. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
159. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ: Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfalazine prophylaxis: A multicenter trial. Digestion 1989;42:224-242.
160. Caprilli R, Andreoli A, Capurso L, Corrao G, D'Albasio G, Gioieni A, Assuero-Lanfranchi G, Paladini I, Pallone F, Ponti V, Rigo G, Rossini F, Sturniolo G, Tonelli F, Valpiani D, and the Gruppo Italiano Per Lo Studio Del Colon e Del Retto (GISC): Oral 5-aminosalicylic acid (Asacol) for prevention of Crohn's disease postoperative recurrences. Aliment Pharmacol Ther 1994;8:35-43.
161. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, D'Arienzo A, D'Albasio G, Pennestri D: Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995;108:345-349.
162. Florent CH, Cortot A, Quandale P, Modi-gliani R, Sarfatl E, Valleur P, Dupas JL, Daurant M, Faucheron JL, Sahmoud T, and the GETAID: Placebo-controlled trial of Mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Eur J Gastroenterol Hepatol 1996;8: 229-233.
163. McLeod RS, Wolff GB, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB: Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109:404-413.
164. Hellers G, Löfberg R, Rutgeerts P, Malchow H, Prantera C, Jewell DP, Cortot A, Pena S, Pallone F, Leijonmarck CE, Gad A, Nilsson LG, Persson T: Oral budesonide for prevention of recurrence following ileocolonic resection of Crohn's disease: A one year placebo-controlled study. Gastroenterology 1996;110:A923.
165. Korelitz B, Hanauer S, Rutgeerts P, Present D, Peppercorn M: Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial. Gastroenterology 1998;114:A1011.
166. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, van Zeben D, Dijkman BAC, Peelers AJ, Jacobs P, van den Brink HR, Schouten HJA, van den Heijde DMFM, Boonen A, van der Linden S: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309-318.
167. Plevy SE, Taylor K, De Woody KL, Schaible TF, Shealy D, Targan SR: Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn's disease (CD) patients with poor clinical responses to monoclonal antibody (cA2). Gastroenterology 1997;112:A1062.